Use: Labeled indications
- VIGAMOX ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE VIGAMOX ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. VIGAMOX is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections.
(1)
Contraindications
4 CONTRAINDICATIONS VIGAMOX is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. VIGAMOX is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Instill one drop in the affected eye 3 times a day for 7 days. VIGAMOX is for topical ophthalmic use. Instill one drop in the affected eye 3 times a day for 7 days. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of VIGAMOX have been established in all ages. Use of VIGAMOX is supported by evidence from adequate and well controlled studies of VIGAMOX in adults, children, and neonates [see Clinical Studies (14)]. There is no evidence that the ophthalmic administration of VIGAMOX has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 5 mg/mL
- Film-coated tablet: 400 mg
- Sterile ophthalmic solution: 5 mg per mL, 5 mg/mL
- Solution for iv infusion: 400 mg/100 mL, 400 mg/250 mL
- ) solution for intravenous infusion: 1.6 mg/mL (400 mg/250 mL
- Sterile ophthalmic ointment: 5 mg/g
- Tablet: 400 mg
- W/v) ophthalmic solution: 5 mg/mL (0.5 %
- ) solution for injection: 1.6 mg/mL (400 mg/250 mL
- Film-coated caplet: 400 mg
and 5 more forms; see the products table.
Registered products in the Philippines
73 products registered with the Food and Drug Administration (FDA) Philippines list Moxifloxacin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Moxifloxcin (1 product). Products registered under these spellings are included in the table and marked.
All registered products73
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
4-QuinMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE bottle with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Importer: Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Limited | DR-XY46546 | Apr 1, 2027 | |
4-QuinMoxifloxacin (as Hydrochloride) | 5mg/ml (0.5% w/v) Ophthalmic Solution5ml LDPE Bottle with Nozzle and Cap (Box of 1's) | Rx | Makcur Laboratories Ltd.India | Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DRP-11229 | Apr 1, 2027 | |
Agua MoxiMoxifloxacin (as Hydrochloride) | 5mg/mL (0.5 % w/v) Sterile Ophthalmic Solution5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's) | Rx | Indiana Ophthalmics LLPIndia | Agua Visions TradingImporter: Medinova Pharmaceutical, Inc. | DRP-13587-02 | Mar 14, 2028 | |
AmoxifloxMoxifloxacin (as hydrochloride) | 5 mg/mL Ophthalmic Solution (Eye Drops)LDPE Bottle x 5 mL (Box of 1's) | Rx | ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines | Trader: SENSOMED PHILS., INC. | DR-XY42705 | Oct 2, 2028 | |
AuromoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drop)2 mL Type I Borosilicate Flint Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip- Off Seal Cap (Net content: 1 mL) (Box of 5's) | Rx | AurolabIndia | Brady Pharma, Inc. | DR-XY48572 | Jan 18, 2028 | |
AveloxMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu blister pack x 5's (Box of 10's) | Rx | Bayer Healthcare Manufacturing S.r.l.Italy | Bayer Philippines, Inc. | DR-XY47545 | Nov 18, 2031 | |
AveloxMoxifloxacin (as Hydrochloride) | 400 mg TabletAlu/Alu Blister Pack x 5's (Box of 20's) | Rx | Bayer AGGermany | Bayer Philippines, Inc. | DR-XY25608 | Mar 30, 2029 | |
AveloxMoxifloxacin (Hydrochloride) | 400 mg/ 250 mL Solution For IV Infusion250 mL Type II colorless glass bottle closed with gray chlorobutyl rubber stopper and aluminum polypropylene flip off seal (Box of 1's) | Rx | Fresenius Kabi Italia S.R.L.Italy | Importer: Bayer Philippines, Inc. | DR-XY47541 | Nov 18, 2026 | |
AxqinMoxifloxacin (as hydrochloride) | 1.6 mg/mL (400 mg/250 mL) Solution for Intravenous InfusionLDPE Bottle with White Dust Cap x 250 mL (Blox of 1's) | Rx | AXA Parenterals LimitedIndia | Brady Pharma Inc. | DRP-9558 | Apr 30, 2031 | |
DemoxifMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 7's (Box of 7's) | Rx | Deva Holding A.S.Turkey | Endure Medical, Inc. | DR-XY49057 | Apr 19, 2029 | |
DespimoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite Opaque Low Density Polyethylene (LDPE) Vial x 10 mL (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | Despina Pharma Inc. | DRP-17922 | Apr 13, 2031 | |
EloximMoxifloxacin (as hydrochloride) | 5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap in 5 mL (net content) (Box of 1’s) | Rx | Indoco Remedies LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7692-03 | Feb 7, 2028 | |
FlorqinMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL Dropper Bottle with Plug and Cap (Box of 1's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Despina Pharma Inc. | DRP-15395 | Jul 3, 2029 | |
Floxquin 400Moxifloxacin (as hydrochloride) | 400mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lee Pharma LimitedIndia | Saifen Drugs Philippines Inc. | DRP-16548 | Apr 22, 2030 | |
FloxsafeMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/ Clear PVC/PVDC Bister pack x 10's (Box of 30's) | Rx | MSN Laboratories Private Limited (Formulations Division)India | Biocare Lifesciences Inc. | DR-3068 | Jun 17, 2031 | |
GoxifloxMoxifloxacin (as hydrochloride) | 400 mg/ 100 mL Solution for IV InfusionLDPE Bottle with Helmet Cap on Topped Bagged in Polypouch x 100 mL (Box of 1's) | Rx | BML Parenteral DrugsIndia | Go Healthcare Pharmaceutical DistributionImporter: Triple Tact Import & Export Corp. | DRP-15418-01 | Jul 5, 2029 | |
IkshamoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13578-02 | Mar 13, 2028 | |
ImoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5%w/v) Ophthalmic SolutionPolypropylene container with pilfer proof polypropylene cap x 5 mL (Box of 1's) | Rx | The ACME Laboratories Ltd.Bangladesh | Euro Generics International Phils., Inc. | DR-XY46085 | Oct 19, 2027 | |
JoyloxinMoxifloxacin | 400 mg/250 mL Solution for IV InfusionUSP Type I Borosilicate Glass Vial with Gray Color Rubber Closure and Aluminum Flip-off Cap x 250 mL | Rx | Korea United Pharm. Inc.Republic of Korea | United Douglas Pharm Philippines, Inc. | DR-XY46600 | Nov 22, 2029 | |
LumemoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)5 mL LDPE Bottle Box of 1's | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-9661 | Apr 23, 2031 | |
MicromoxMoxifloxacin ( as hydrochloride ) | 5 mg/mL ( 0.5% w/v) Ophthalmic Solution ( Eye Drops )5mL ( net content ) in 5 mL Low Density Polyethylene ( LDPE ) screw type neck bottle with translucent cone shaped LDPE open nozzle and white High Density Polyethylene ( HDPE ) screw cap Box of 1's | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY46508 | Jan 24, 2029 | |
MilfloxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic SolutionLDPE Dropper Bottle with HDPE pilfer-proof cap x 5 mL (Box of 1's) | Rx | Sun Pharmaceutical Medicare LimitedIndia | Sun Pharma Philippines, Inc.Trader: Sun Pharmaceutical Industries Ltd. | DRP-8603 | Aug 2, 2028 | |
Mo-FlorenMoxifloxacin (as hydrochloride) | 5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1's) | Rx | Indoco Remedies LimitedIndia | Ambica International Corporation | DRP-7692 | Feb 7, 2028 | |
MoflodexMoxifloxacin (As Hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL capacity White opaque LDPE Plastic Bottle with White LDPE Nozzle and White LDPE Cap x 3 mL (Box of 1's) | Rx | Pt. Ferron Par PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc. | DRP-18473 | Jul 21, 2031 | |
Mosi Eye DropsMoxifloxacin Hydrochloride | 5 mg/mL (0.5% w/w) Ophthalmic Solution (Eye Drops)5 mL LDPE Dropper Bottle (Box of 1's) | Rx | FDC LIMITED INC.India | Penta Labs Australia (Philippines) | DRP-10768 | Nov 18, 2026 | |
MoxeteroMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-6896 | Mar 12, 2027 | |
MoxflakemMoxifloxacin (as hydrochloride) | 5 mg / mL (0.5 % w/v) Ophthalmic SolutionLDPE Dropper Bottle Sealed with White HDPE Screw Cap x 5 mL (Box of 1’s) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Sankem Healthcare Inc.Importer: Ambica International Corporation | DRP-13374-01 | Feb 8, 2028 | |
MoxflozMoxifloxacin (as Hydrochloride) | 5 mg / mL (0.5% w/v) Sterile Ophthalmic Solution5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ophtha Pharma Traders Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13587-01 | Mar 14, 2028 | |
MoxflozMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionLDPE Bottle with nozzle and cap x 5 ml (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ophtha Pharma Traders Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13578-05 | Mar 13, 2028 | |
MoxianaMoxifloxacin (as Hydrochloride) | 5 mg/g (0.5% w/w) Ophthalmic OintmentAluminum tube x 5 g (Box of 1's) | Rx | Indiana OphthalmicsIndia | Aglobal Care Inc.Importer: Aglobal Care, Inc. | DRP-13478 | Feb 27, 2028 | |
MoxiDenMoxifloxacin (as Hydrochloride) | 5mg/mL (0.5% w/v) Ophthalmic Solution5ml LDPE Bottle with Nozzle and Cap (Box of 1's) | Rx | Makcur Laboratories Ltd.India | D&M Pharma Corp.Importer: Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DRP-11229-01 | Apr 1, 2027 | |
MoxidinMoxifloxacin (as hydrochloride) | 5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1’s) | Rx | Indoco Remedies LimitedIndia | Medchoice Vision Care Inc.Importer: Ambica International Corporation | DRP-7692-02 | Feb 7, 2028 | |
MoxidinMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionLDPE bottle with HDPE cap (Box of 1's) | Rx | Hanlim Pharm. Co., Ltd.Republic of Korea | Medchoice Vision Care Inc.Importer: JLT Pharma Inc. | DRP-11720-01 | Apr 22, 2027 | |
MoxidinMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Medchoice Vision Care Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13578-03 | Mar 13, 2028 | |
MoxidropMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)15 mL LDPE Bottle (10 mL net content) with white plug and white cap (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-14791 | Jan 9, 2029 | |
Moxif EyeMoxifloxacin (as Hydrochloride). | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Vial Sealed with HDPE Cap and LDPE Nozzle x 5 mL (Box of 1's). | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation | DRP-15646 | Aug 14, 2029 | |
MoxifloMoxifloxacin (as hydrochloride) | 1.6 mg/mL (400 mg/250 mL) Solution for Intravenous Infusion300 mL-capacity USP Type II transparent glass bottle containing 250 mL (net content) with rubber stopper and aluminum cap (Box of 1’s) | Rx | Sui Guan Chem. Ind. Co., Ltd.Taiwan | Caan Pharmaceutical Co., Inc. | DRP-12149 | Jun 21, 2027 | |
MoxiflostadMoxifloxacin | 400mg (equivalent to 436.80mg Moxifloxacin hydrochloride) Film-Coated TabletAlu / PVC-PVDC Blister Pack x 5's (Box of 5's) | Rx | Hemofarm A.D.Serbia | Stada Philippines Inc.Trader: Stada Arzneimittel AG | DRP-11513 | Mar 30, 2027 | |
MoxiflovicMoxifloxacin (as Hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 20’s) | Rx | XL Laboratories Pvt. Ltd.India | Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation | DRP-8575-01 | Jul 23, 2031 | |
MoxifloxMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril International Co., Inc.Trader: Totalcare Pharma Inc. | DRP-15314 | Jul 26, 2031 | |
MoxifloxMoxifloxacin hydrochloride | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-5432 | Oct 23, 2029 | |
MoxiforceMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5%w/v) Ophthalmic SolutionLDPE bottle with HDPE cap (Box of 1's ) | Rx | Hanlim Pharm. Co., Ltd.Korea | JLT Pharma, Inc. | DRP-11720 | Apr 22, 2027 | |
MoxileeMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Lee Pharma LimitedIndia | Aglobal Care, Inc. | DRP-14398 | Aug 31, 2028 | |
MoximaxMoxifloxacin (as hydrochloride) | 5mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Bottle with White Screw Cap x 5mL (Box of 1’s) | Rx | Makers Laboratories LtdIndia | Blue Global (FZE) | DRP-18137 | May 13, 2031 | |
MoxiquinMoxifloxacin (as hydrochloride) | 400 mg/100 mL Solution for IV InfusionLDPE Bottle with Helmet Cap on Topped Bagged in Polypouch x 100 mL (Box of 1's) | Rx | BML Parenteral DrugsIndia | Triple Tact Import & Export Corp.Trader: Alwin DMD Pharmaceuticals | DRP-15418 | Jul 5, 2029 | |
MoxisaphMoxifloxacin (As Hydrochloride) | 5 mg/mL (0.5% w/w) Sterile Ophtahlmic SolutionWhite HDPE Dropper Bottle with Close Nozzle and Single Pilfer Proof ring cap x 5 mL (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13164 | Dec 13, 2027 | |
MoxivellMoxifloxacin (as hydrochloride) | 400 mg Film-Coated CapletAluminum foil strip x 10's (Box of 10's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY47063 | Sep 23, 2031 | |
Moxiwar 400Moxifloxacin hydrochloride | 400 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 7's (Box of 7's) | Rx | Aurobindo Pharma Limited-Unit VIIIndia | AAA Pharma, Inc. | DR-XY47907 | Apr 6, 2027 | |
MoxopthaMoxifloxacin (as hydrochloride) | 5 mg/g (0.5% w/w) Sterile Ophthalmic OintmentAluminum Collapsible Tube x 5 g (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-17394 | Dec 10, 2030 | |
MoxxilMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14614 | Oct 27, 2028 | |
NoneMoxifloxacin (as hydrochloride) | 400 mg Film-coated tabletAlu/Alu Blister Pack of 5 tablets (Box of 5 tablets) | Rx | Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan | AAA Pharma, Inc. | DR-XY45835 | Mar 27, 2027 | |
NoneMoxifloxacin (as hydrochloride) | 400 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 20’s) | Rx | XL Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-8575 | May 25, 2031 | |
NoneMoxifloxacin (as Hydrochloride) | 5 mg / mL (0.5 % w/v) Ophthalmic SolutionWhite LDPE Dropper Bottle with HDPE Tamper-Evident Screw Cap x 5 mL (Box of 1’s) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Ritemed Phils., Inc.Importer: Aglobal Care | DRP-11536-01 | Oct 24, 2027 | |
NoneMoxifloxacin (as hydrochloride) | 5 mg / mL (0.5 % w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Celsus Pharmaceuticals Phils., Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13578-01 | Mar 13, 2028 | |
OcumoxMoxifloxacin (as hydrochloride) | 5 mg/g Sterile Ophthalmic OintmentAluminum Collapsible Tube x 3.5g (Box of 1's) | Rx | Remington Pharmaceutical industries (Pvt.) Ltd.Pakistan | Ophthamed Pharma Corp. | DRP-12248 | Mar 19, 2030 | |
OcumoxMoxifloxacin Hydrochloride | 5mg/mL Sterile Ophthalmic SolutionLow Density Polyethylene (LDPE) Plastic Vial with Dropping Nozzle and Hard PVC Cap x 5 mL Box of 1's | Rx | Remington Pharmaceutical industries (Pvt.) Ltd.Pakistan | OPHTHAMED PHARMA CORP. | DRP-12277 | Oct 11, 2028 | |
OflokasinMoxifloxacin | 400mg/ 250mL Solution for Infusion250mL Type II Glass bottle with grey rubber stopper and aluminum cap with flip-off seal (Box of 1's) | Rx | Anfarm Hellas S.A.Greece | Saifen Drugs Philippines Inc. | DRP-16862 | Jul 30, 2030 | |
OpmoxinMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite LDPE Dropper Bottle with HDPE Tamper-Evident Screw Cap X 5 mL (Box of 1’s) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Aglobal Care, Inc. | DRP-11536 | Oct 24, 2027 | |
OpthomoxMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution.5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's) | Rx | Indiana OphthalmicsIndia | Medinova Pharmaceutical Inc. | DRP-13587 | Mar 14, 2028 | |
OptimoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5%) Ophthalmic Solution (Eye Drops)White Opaque LDPE Plastic Dropper Bottle x 5 mL with white Opaque HDPE Plastic cap (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading Inc. | DRP-6998 | May 18, 2031 | |
OptiwellMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE vial with LDPE nozzle and white HDPE cap (Box of 1's) | Rx | Indoco Remedies Limited Plant IIIndia | Despina Pharma Inc. | DRP-14889 | Jan 31, 2029 | |
PlaxomibMoxifloxacin (as Hydrochloride) | 5 mg/mL (0.5% 0.5% w/v) Ophthalmic SolutionLDPE Dropper Bottle Sealed with White HDPE Screw Cap x 5 mL (Box of 1's) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Ambica International Corporation | DRP-13374 | Feb 8, 2028 | |
Pol-MoxiMoxifloxacin (as hydrochloride) | 400 mg/ 250 mL Solution for I.V. Infusion250 mL Polypropylene bag with SFC port and SFC cap (Box of 1's) | Rx | Polifarma Ilac San Ve. Tic. A.S.Turkey | Endure Medical Inc. | DR-XY48663 | Mar 22, 2028 | |
QuinoftaMoxifloxacin (as hydrochloride) | 5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1’s) | Rx | Indoco Remedies LimitedIndia | Ophthamed Pharma Corp.Importer: Ambica International Corporation | DRP-7692-01 | Feb 7, 2028 | |
SensomoxMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Sensorycare Pharma Co.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13578-04 | Mar 13, 2028 | |
SvozMoxifloxacin (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite Opaque LDPE Plastic Bottle with Eye Tip and Pale Blue HDPE Plastic Screw Cap x 5 mL (Box of 1's) | Rx | Siam Bheasach Co., Ltd.Thailand | Endure Medical, IncTrader: Siampharmaceutical Co., | DR-XY49231 | Sep 25, 2029 | |
VeloxinMoxifloxacin (as Hydrochloride) | 400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | Pacific Pharmaceuticals LimitedPakistan | Raquel Abbas Pharma Inc. | DRP-15567 | Aug 2, 2029 | |
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE White Bottle with HDPE White Cap x 5 ML (Box of 1's) | Rx | Laboratorios Ashford L.D.A.China | Marrion Pharma Inc. | DR-XY49789 | Sep 3, 2031 | ||
VigamoxMoxifloxacin (As Hydrochloride) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution5 mL in LDPE Plastic Bottle (droptainer) (box of 1's) | Rx | Alcon-Couvreur NVBelgium | Novartis Healthcare Philippines, Inc. | DR-XY30956 | Jun 20, 2028 | |
VistamoxMoxifloxacin Hydrochloride | 5 mg/mL (0.50% w/v) Ophthalmic Solution (Drops)5 mL net volume in White LDPE Plastic Bottle with White LDPE Nozzle and White HDPE Cap x 10 mL (Box of 1’s) | Rx | EL Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY42590 | Oct 7, 2030 | |
XifloxMoxifloxacin Hydrochloride | 1.6 mg/ mL (400 mg / 250 mL) Solution for Injection (IV Infusion)USP Type II Clear Glass Vial with grey rubber stopper and blue flip-off seal (Box of 1’s) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY44737 | Aug 4, 2031 | |
XifloxMoxifloxacin (as hydrochloride) | 400mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 5's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY48624 | Feb 14, 2028 | |
(no brand name)Moxifloxacin (as hydrochloride) | 400mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 100's) | Rx | Lupin LimitedIndia | Lupin Philippines, Inc. | DR-XY48994 | Jan 31, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing moxifloxacin 0.5%. Ophthalmic solution containing moxifloxacin 0.5%. (3)
Warnings/Precautions
- Hypersensitivity Reactions: Hypersensitivity and anaphylaxis have been reported with systemic use of moxifloxacin. (5.1)
- Prolonged Use: May result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. (5.2)
- Avoid Contact Lens Wear: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis. (5.3)
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching.
If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.
5.2 Growth of Resistant Organisms With Prolonged Use
5.2 Growth of Resistant Organisms With Prolonged Use As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
5.3 Avoidance of Contact Lens Wear
5.3 Avoidance of Contact Lens Wear Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with VIGAMOX ®. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.
These events occurred in approximately 1%-6% of patients. Nonocular adverse events reported at a rate of 1%-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.
These events occurred in approximately 1% to 6% of patients. (6) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 844-446-6979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with VIGAMOX ® in pregnant women to inform any drug-associated risks. Oral administration of moxifloxacin to pregnant rats and monkeys and intravenously to pregnant rabbits during the period of organogenesis did not produce adverse maternal or fetal effects at clinically relevant doses.
Oral administration of moxifloxacin to pregnant rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses (see Data). Data Animal Data Embryo-fetal studies were conducted in pregnant rats administered with 20, 100, or 500 mg/kg/day moxifloxacin by oral gavage on Gestation Days 6 to 17, to target the period of organogenesis.
Decreased fetal body weight and delayed skeletal development were observed at 500 mg/kg/day [277 times the human area under the curve (AUC) at the recommended human ophthalmic dose]. The No-Observed-Adverse-Effect-Level (NOAEL) for developmental toxicity was 100 mg/kg/day (30 times the human AUC at the recommended human ophthalmic dose).
Embryo-fetal studies were conducted in pregnant rabbits administered with 2, 6.5, or 20 mg/kg/day moxifloxacin by intravenous administration on Gestation Days 6 to 20, to target the period of organogenesis. Abortions, increased incidence of fetal malformations, delayed fetal skeletal ossification, and reduced placental and fetal body weights were observed at 20 mg/kg/day (1086 times the human AUC at the recommended human ophthalmic dose), a dose that produced maternal body weight loss and death.
The NOAEL for developmental toxicity was 6.5 mg/kg/day (246 times the human AUC at the recommended human ophthalmic dose). Pregnant cynomolgus monkeys were administered moxifloxacin at doses of 10, 30, or 100 mg/kg/day by intragastric intubation between Gestation Days 20 and 50, targeting the period of organogenesis. At the maternal toxic doses of ≥ 30 mg/kg/day, increased abortion, vomiting, and diarrhea were observed.
Smaller fetuses/reduced fetal body weights were observed at 100 mg/kg/day (2864 times the human AUC at the recommended human ophthalmic dose). The NOAEL for fetal toxicity was 10 mg/kg/day (174 times the human AUC at the recommended human ophthalmic dose). In a pre- and postnatal study, rats were administered moxifloxacin by oral gavage at doses of 20, 100, and 500 mg/kg/day from Gestation Day 6 until the end of lactation.
Maternal death occurred during gestation at 500 mg/kg/day. Slight increases in the duration of pregnancy, reduced pup birth weight, and decreased prenatal and neonatal survival were observed at 500 mg/kg/day (estimated 277 times the human AUC at the recommended human ophthalmic dose). The NOAEL for pre- and postnatal development was 100 mg/kg/day (estimated 30 times the human AUC at the recommended human ophthalmic dose).
Mechanism of action
12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4)].
US FDA labelPharmacokinetics
The plasma half-life of moxifloxacin was estimated to be 13 hours.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX ® 3 times a day. The mean steady-state C max (2.7 ng/mL) and AUC 0-∞ (41.9 ng●hr/mL) values were 1600 and 1100 times lower than the mean C max and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Moxifloxacin 5 mg/mL, 5 mL Ophthalmic Solution | ₱320.00–₱493.00Reference ₱493.00 | per unit | DPRI procurement range |
| Moxifloxacin (as Hydrochloride) 400 mg Film coated tablet | ₱71.20–₱103.67Reference ₱71.20 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Moxifloxacin |
| PNF listing | Oral: 400 mg film coated tablet |
| PNF listing | Ophthalmic solution: 5 mg/mL (0.5% w/v) sterile ophthalmic solution, 5 mL bottle (as hydrochloride) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. VIGAMOX · Harrow Eye, LLC [US FDA-approved label, version 4, January 22, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12053b08-7e66-c6f3-e063-6394a90a9cd9
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
